Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMID 25122144)

Published in Genet Med on August 14, 2014

Authors

Robert Shenkar1, Changbin Shi1, Tania Rebeiz2, Rebecca A Stockton3, David A McDonald4,5, Abdul Ghani Mikati1, Lingjiao Zhang1, Cecilia Austin1, Amy L Akers6, Carol J Gallione4, Autumn Rorrer4, Murat Gunel7, Wang Min8, Jorge Marcondes De Souza9, Connie Lee6, Douglas A Marchuk4, Issam A Awad1,2

Author Affiliations

1: Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine, Chicago, IL 60637, USA.
2: Department of Neurology, The University of Chicago Medicine, Chicago, IL 60637, USA.
3: Department of Pediatrics, University of California at Los Angeles, Torrance, CA 90502, USA.
4: Department of Molecular Genetics and Microbiology, Duke University, Durham, NC 27710, USA.
5: Center for Science, Math and Technology Education, North Carolina Central University, Durham, NC 27707, USA.
6: Angioma Alliance, Norfolk, VA 23510, USA.
7: Departments of Neurosurgery and Neurobiology, Yale University, New Haven, CT 06520, USA.
8: Department of Pathology, Yale University, New Haven, CT 06520, USA.
9: Department of Neurosurgery, School of Medicine, Federal University of Rio De Janeiro, Rio de Janeiro, Brazil.

Articles citing this

Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. Nat Med (2016) 1.39

Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. Proc Natl Acad Sci U S A (2015) 1.09

Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab (2015) 0.82

Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol (2016) 0.79

Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med (2016) 0.76

Introduction to cerebral cavernous malformation: a brief review. BMB Rep (2016) 0.76

Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci (2015) 0.76

Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods (2016) 0.76

Downregulation of programmed cell death 10 is associated with tumor cell proliferation, hyperangiogenesis and peritumoral edema in human glioblastoma. BMC Cancer (2015) 0.75

RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke (2016) 0.75

Constitutional de novo and postzygotic mutations in isolated cases of cerebral cavernous malformations. Mol Genet Genomic Med (2016) 0.75

The pathobiology of vascular malformations: insights from human and model organism genetics. J Pathol (2016) 0.75

Cerebral Cavernous Malformations: Review of the Genetic and Protein-Protein Interactions Resulting in Disease Pathogenesis. Front Surg (2016) 0.75

FAM222B Is Not a Likely Novel Candidate Gene for Cerebral Cavernous Malformations. Mol Syndromol (2016) 0.75

Clinical Management of Cavernous Malformations. Curr Cardiol Rep (2017) 0.75

Articles cited by this

The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg (1994) 3.06

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med (2009) 3.05

EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature (2013) 2.70

Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62

Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Sci Transl Med (2011) 2.35

Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med (2010) 2.23

Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13

Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet (2008) 1.95

Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke (2011) 1.91

Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke (2008) 1.87

The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1δ. Arch Biochem Biophys (2011) 1.86

Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol (2012) 1.79

Evaluating strategies for the treatment of cerebral cavernous malformations. Stroke (2010) 1.77

Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke (2005) 1.70

The natural history of intracranial cavernous malformations. Neurosurg Focus (2011) 1.68

Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: inhibitory effects and occurrence in A7r5 cells. FEBS Lett (2005) 1.59

Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol (2006) 1.55

Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem (2010) 1.51

Intracranial cavernous malformations: lesion behavior and management strategies. Neurosurgery (1995) 1.41

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet (2010) 1.39

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest (2011) 1.36

CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci (2010) 1.35

A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol (2008) 1.27

Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum Mutat (2006) 1.24

STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol (2013) 1.13

Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery (2008) 1.12

Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. Cell Mol Life Sci (2013) 1.08

CCM3/PDCD10 heterodimerizes with germinal center kinase III (GCKIII) proteins using a mechanism analogous to CCM3 homodimerization. J Biol Chem (2011) 1.05

Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery (2006) 1.05

CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Mol Syndromol (2013) 1.03

Ccm3 functions in a manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular disease. Dev Biol (2011) 0.99

Mutation analysis of CCM1, CCM2 and CCM3 genes in a cohort of Italian patients with cerebral cavernous malformation. Brain Pathol (2010) 0.97

Immune response in human cerebral cavernous malformations. Stroke (2009) 0.94

A network of interactions enables CCM3 and STK24 to coordinate UNC13D-driven vesicle exocytosis in neutrophils. Dev Cell (2013) 0.93

Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med (2013) 0.92

Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations. Neurology (2001) 0.92

Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol (2009) 0.88

Ccm3, a gene associated with cerebral cavernous malformations, is required for neuronal migration. Development (2014) 0.88

Cavernous malformations and hemorrhage risk. Prog Neurol Surg (2012) 0.81

Genetic and cellular basis of cerebral cavernous malformations: implications for clinical management. Clin Genet (2012) 0.80